Prediction of major adverse cardiovascular events (MACE): univariable and multivariable analysis
| Hazard ratio (95% CI) | ||||||
| Univariable | p | Multivariable | p | Multivariable (Echo subgroup) | p | |
| Variable | ||||||
| Age | 1.048 (1.040 to 1.057) | <0.001 | 1.024 (1.014 to 1.035) | <0.001 | 1.029 (1.016 to 1.042) | <0.001 |
| Male gender | 0.749 (0.625 to 0.897) | 0.002 | 1.157 (0.936 to 1.429) | 0.178 | 1.006 (0.779 to 1.043) | 0.963 |
| History of: | ||||||
| Hypertension | 1.597 (1.345 to 1.895) | <0.001 | 1.169 (0.957 to 1.427) | 0.149 | 1.338 (1.043 to 1.716) | 0.02 |
| CHD (MI/angina) | 1.681 (1.418 to 1.992) | <0.001 | 1.350 (1.105 to 1.649) | 0.003 | 1.220 (0.955 to 1.559) | 0.112 |
| Diabetes | 1.711 (1.424 to 2.056) | <0.001 | 1.236 (0.980 to 1.559) | 0.073 | 1.013 (0.753 to 1.361) | 0.934 |
| Heart failure | 1.476 (1.002 to 2.175) | 0.049 | ||||
| STEMI/NSTEMI | 0.919 (0.771 to 1.097) | 0.350 | – | – | – | – |
| Anterior/other site | 1.061 (0.892 to 1.261) | 0.505 | – | – | – | – |
| Killip class | 1.766 (1.584-1.970) | <0.001 | 1.214 (0.969 to 1.519) | 0.008 | 1.056 (0.801 to 1.392) | 0.698 |
| eGFR | 0.972 (0.968 to 0.977) | <0.001 | 0.992 (0.985 to 0.997) | 0.003 | 0.993 (0.986 to 1.000) | 0.003 |
| Glucose | 1.056 (1.038 to 1.074) | <0.001 | 1.015 (0.995 to 1.036) | 0.134 | 1.028 (1.001 to 1.056) | 0.046 |
| Troponin I | 1.097 (0.945 to 1.272) | 0.223 | ||||
| Aspirin | 0.506 (0.404 to 0.635) | <0.001 | 0.723 (0.556 to 0.940) | 0.016 | 0.852 (0.621 to 1.169) | 0.321 |
| β Blocker | 0.535 (0.446 to 0.642) | <0.001 | 0.741 (0.599 to 0.917) | 0.006 | 0.793 (0.601 to 1.045) | 0.100 |
| ACEI/ARB | 0.965 (0.801 to 1.162) | 0.705 | 2.011 (1.064 to 3.801) | 0.031 | 6.250 (1.275 to 30.627) | 0.024 |
| Statin | 0.716 (0.596 to 0.859) | <0.001 | 1.112 (0.893 to 1.384) | 0.343 | 1.23 (0.928 to 1.630) | 0.15 |
| CCB | 1.230 (0.998 to 1.517) | 0.052 | 1.015 (0.799 to 1.289) | 0.904 | 0.951 (0.696 to 1.299) | 0.752 |
| Diuretic | 1.825 (1.538 to 2.165) | <0.001 | 1.08 (0.870 to 1.341) | 0.484 | 1.26 (0.968 to 1.639) | 0.086 |
| Thrombolytic agent | 0.796 (0.637 to 0.994) | 0.044 | 0.912 (0.733 to 1.136) | 0.412 | 1.000 (0.762 to 1.314) | 0.998 |
| In-hospital revascularisation | 0.925 (0.709 to 1.206) | 0.565 | – | – | – | – |
| Echocardiographic LV systolic dysfunction | 2.107 (1.710 to 2.596) | 0.001 | 1.467 (1.145 to 1.879) | 0.002 | ||
| Log NT-proBNP | 2.417 (2.099 to 2.784) | <0.001 | 1.713 (1.438 to 2.040) | <0.001 | 2.25 (1.695 to 2.985) | <0.001 |
Multivariable analysis was carried out first including log NT-proBNP as a continuous variable, then substituting data categorised by quartile of NT- proBNP, which was finally replaced by a term for interaction between prescription of ACEI/ARB and quartile of NT-proBNP (quartile 4 compared with quartiles 1–3).
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; CHD, coronary heart disease—that is, myocardial infarction or angina; CK, creatine kinase; eGFR, estimated glomerular filtration rate; MI, myocardial infarction; NSTEMI, non-ST elevation myocardial infarction; STEMI, ST elevation myocardial infarction.